InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-26 | 2026-03-02 | AI Biotechnology LLC | 10% Owner | Purchase | 2.00M | $6.25 | $12.50M | 6.55M | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research and development | $42.1M+72.5% | $24.4M-44.5% | $44.0M+85.7% | $23.7M |
| General and administrative | $33.2M+7.7% | $30.8M+65.2% | $18.6M+436.7% | $3.5M |
| Total operating expenses | $75.2M+36.3% | $55.2M-11.9% | $62.6M+130.6% | $27.2M |
| Loss from operations | -$75.2M-36.3% | -$55.2M+11.9% | -$62.6M-130.6% | -$27.2M |
| Interest income | -$6.3M+20.8% | -$8.0M-265.9% | -$2.2M-27225.0% | -$8K |
| Change in fair value of private placement warrants | $5.2M | — | -$724K-200.0% | $724K |
| Other income, net | -$260K-828.6% | -$28K-64.7% | -$17K | — |
| Total other income, net | -$6.6M-136.8% | -$2.8M-34.3% | -$2.1M | — |
| Loss before income taxes | -$68.7M-31.0% | -$52.4M+13.5% | -$60.6M-121.6% | -$27.3M |
| Income tax benefit | — | — | — | $0 |
| Net loss | -$68.7M-31.0% | -$52.4M+13.2% | -$60.4M-134.5% | -$25.7M |
| Adjustment of redeemable noncontrolling interest | $831K-88.2% | $7.0M | — | — |
| Accretion of redeemable noncontrolling interest to redemption value | $4.9M | — | — | -$6.7M |
| Deemed dividend on extinguishment of noncontrolling interest and redeemable noncontrolling interest | -$36.4M | — | — | — |
| Net loss attributable to Class A Ordinary Shareholders of Zura | -$99.4M-118.9% | -$45.4M+34.5% | -$69.2M-113.8% | -$32.4M |
| Net loss per share attributable to Class A Ordinary Shareholders of Zura, basic (in dollars per share) | -$1K-76.7% | -$600+71.3% | -$2K+98.5% | -$142K |
| Net loss per share attributable to Class A Ordinary Shareholders of Zura, diluted (in dollars per share) | -$1K-76.7% | -$600+71.3% | -$2K+98.5% | -$142K |
| Weighted-average Class A Ordinary Shares used in computing net loss per share attributable to Class A Ordinary Shareholders of Zura, basic (in shares) | $94.16B+25.4% | $75.07B+127.0% | $33.06B+14392.4% | $228.1M |
| Weighted-average Class A Ordinary Shares used in computing net loss per share attributable to Class A Ordinary Shareholders of Zura, diluted (in shares) | $94.16B+25.4% | $75.07B+127.0% | $33.06B+14392.4% | $228.1M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
Zura Bio GAAP EPS of -$0.22
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates